Efficacy and safety of low dose mycophenolate mofetile for remission maintenance in ANCA-associated vasculitis

Efficacy and safety of low dose mycophenolate mofetile for remission maintenance in ANCA-associated vasculitis - Low dose mycophenolate mofetile as maintenance therapy in ANCA-associated vasculitis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005242

Enrollment

Registered

2011-05-01

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ANCA associated vasculitis

Interventions

MMF 500~1000mg/day 24 months follow up

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ANCA associated vasculitis state of remission patients gave written informed consent for participation in the study

Exclusion criteria

Exclusion criteria: WBC<3000/mm3 pregnant women combine with other immunosuppressant within 4 weeks

Design outcomes

Primary

Measure	Time frame
relapse rate	—

Secondary

Measure	Time frame
1,side effect of steroid 2,safety of MMF 3,VDI, SF36, QOL	—

Countries

Japan

Contacts

Public ContactMitsuyo Itabashi

Kidney Center, Tokyo Women's Medical University Department of Medicine

m-itaba@fb4.so-net.ne.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026